1-20 of 56
Mark G. Kris
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Tumor-Agnostic Genomic and Clinical Analysis of BRAF Fusions Identifies Actionable Targets

Monica F. Chen, Soo-Ryum Yang, Jessica J. Tao, Antoine Desilets, Eli L. Diamond, Clare Wilhelm, Ezra Rosen, Yixiao Gong, Kerry Mullaney, Jean Torrisi, Robert J. Young, Romel Somwar, Helena A. Yu, Mark G. Kris, Gregory J. Riely, Maria E. Arcila, Marc Ladanyi, Mark T.A. Donoghue, Neal Rosen, Rona Yaeger, Alexander Drilon, Yonina R. Murciano-Goroff, Michael Offin
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (17): 3812–3823.
https://doi.org/10.1158/1078-0432.CCR-23-3981
Published: 03 September 2024
View article titled, Tumor-Agnostic Genomic and Clinical Analysis of <em>BRAF</em> Fusions Identifies Actionable Targets
Open the PDF for Tumor-Agnostic Genomic and Clinical Analysis of <em>BRAF</em> Fusions Identifies Actionable Targets in another window
Includes: Supplementary data
Journal Articles

Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer

Rohit Thummalapalli, Biagio Ricciuti, Chaitanya Bandlamudi, Daniel Muldoon, Hira Rizvi, Arielle Elkrief, Jia Luo, Joao V. Alessi, Federica Pecci, Giuseppe Lamberti, Alessandro Di Federico, Lingzhi Hong, Jianjun Zhang, John V. Heymach, Don L. Gibbons, Andrew J. Plodkowski, Vignesh Ravichandran, Mark T.A. Donoghue, Chad Vanderbilt, Marc Ladanyi, Charles M. Rudin, Mark G. Kris, Gregory J. Riely, Jamie E. Chaft, Matthew D. Hellmann, Natalie I. Vokes, Mark M. Awad, Adam J. Schoenfeld
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (21): 4408–4418.
https://doi.org/10.1158/1078-0432.CCR-23-1207
Published: 01 November 2023
View article titled, Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer
Open the PDF for Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer in another window
Includes: Supplementary data
Journal Articles

Brief Report: Combination of Osimertinib and Dacomitinib to Mitigate Primary and Acquired Resistance in EGFR-Mutant Lung Adenocarcinomas

Arielle Elkrief, Alex Makhnin, Khadeja A. Moses, Linda S. Ahn, Isabel R. Preeshagul, Afsheen N. Iqbal, Sara A. Hayes, Andrew J. Plodkowski, Paul K. Paik, Marc Ladanyi, Mark G. Kris, Gregory J. Riely, Franziska Michor, Helena A. Yu
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (8): 1423–1428.
https://doi.org/10.1158/1078-0432.CCR-22-3484
Published: 14 April 2023
View article titled, Brief Report: Combination of Osimertinib and Dacomitinib to Mitigate Primary and Acquired Resistance in <em>EGFR</em>-Mutant Lung Adenocarcinomas
Open the PDF for Brief Report: Combination of Osimertinib and Dacomitinib to Mitigate Primary and Acquired Resistance in <em>EGFR</em>-Mutant Lung Adenocarcinomas in another window
Includes: Supplementary data
Journal Articles

Response to Standard Therapies and Comprehensive Genomic Analysis for Patients with Lung Adenocarcinoma with EGFR Exon 20 Insertions

Noura J. Choudhury, Adam J. Schoenfeld, Jessica Flynn, Christina J. Falcon, Hira Rizvi, Charles M. Rudin, Mark G. Kris, Maria E. Arcila, Glenn Heller, Helena A. Yu, Marc Ladanyi, Gregory J. Riely
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2021) 27 (10): 2920–2927.
https://doi.org/10.1158/1078-0432.CCR-20-4650
Published: 15 May 2021
View article titled, Response to Standard Therapies and Comprehensive Genomic Analysis for Patients with Lung Adenocarcinoma with <em>EGFR</em> Exon 20 Insertions
Open the PDF for Response to Standard Therapies and Comprehensive Genomic Analysis for Patients with Lung Adenocarcinoma with <em>EGFR</em> Exon 20 Insertions in another window
Includes: Supplementary data
Journal Articles

Treatment Outcomes and Clinical Characteristics of Patients with KRAS-G12C–Mutant Non–Small Cell Lung Cancer

Kathryn C. Arbour, Hira Rizvi, Andrew J. Plodkowski, Matthew D. Hellmann, Andrea Knezevic, Glenn Heller, Helena A. Yu, Marc Ladanyi, Mark G. Kris, Maria E. Arcila, Charles M. Rudin, Piro Lito, Gregory J. Riely
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (8): 2209–2215.
https://doi.org/10.1158/1078-0432.CCR-20-4023
Published: 15 April 2021
View article titled, Treatment Outcomes and Clinical Characteristics of Patients with KRAS-G12C–Mutant Non–Small Cell Lung Cancer
Open the PDF for Treatment Outcomes and Clinical Characteristics of Patients with KRAS-G12C–Mutant Non–Small Cell Lung Cancer in another window
Journal Articles

MET Exon 14–altered Lung Cancers and MET Inhibitor Resistance

Robin Guo, Michael Offin, A. Rose Brannon, Jason Chang, Andrew Chow, Lukas Delasos, Jeffrey Girshman, Olivia Wilkins, Caroline G. McCarthy, Alex Makhnin, Christina Falcon, Kerry Scott, Yuan Tian, Fabiola Cecchi, Todd Hembrough, Deepu Alex, Ronglai Shen, Ryma Benayed, Bob T. Li, Charles M. Rudin, Mark G. Kris, Maria E. Arcila, Natasha Rekhtman, Paul Paik, Ahmet Zehir, Alexander Drilon
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (3): 799–806.
https://doi.org/10.1158/1078-0432.CCR-20-2861
Published: 01 February 2021
View article titled, <em>MET</em> Exon 14–altered Lung Cancers and MET Inhibitor Resistance
Open the PDF for <em>MET</em> Exon 14–altered Lung Cancers and MET Inhibitor Resistance in another window
Includes: Supplementary data
Journal Articles

Abstract IA04: COVID-19 in patients with lung cancers in New York City

Jia Luo, Hira Rizvi, Isabel R. Preeshagul, Jacklynn V. Egger, David Hoyos, Chaitanya Bandlamudi, Mark T.A. Donoghue, Marta Łuksza, Benjamin D. Greenbaum, Jedd D. Wolchok, Mark G. Kris, Matthew D. Hellmann
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (18_Supplement): IA04.
https://doi.org/10.1158/1557-3265.COVID-19-IA04
Published: 15 September 2020
View article titled, Abstract IA04: COVID-19 in patients with lung cancers in New York City
Journal Articles

MAPK Pathway Alterations Correlate with Poor Survival and Drive Resistance to Therapy in Patients with Lung Cancers Driven by ROS1 Fusions

Hiroki Sato, Adam J. Schoenfeld, Evan Siau, Yue Christine Lu, Huichun Tai, Ken Suzawa, Daisuke Kubota, Allan J.W. Lui, Besnik Qeriqi, Marissa Mattar, Michael Offin, Masakiyo Sakaguchi, Shinichi Toyooka, Alexander Drilon, Neal X. Rosen, Mark G. Kris, David Solit, Elisa De Stanchina, Monika A. Davare, Gregory J. Riely, Marc Ladanyi, Romel Somwar
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (12): 2932–2945.
https://doi.org/10.1158/1078-0432.CCR-19-3321
Published: 15 June 2020
View article titled, MAPK Pathway Alterations Correlate with Poor Survival and Drive Resistance to Therapy in Patients with Lung Cancers Driven by <em>ROS1</em> Fusions
Open the PDF for MAPK Pathway Alterations Correlate with Poor Survival and Drive Resistance to Therapy in Patients with Lung Cancers Driven by <em>ROS1</em> Fusions in another window
Includes: Supplementary data
Journal Articles

Circulating Tumor DNA Analysis to Assess Risk of Progression after Long-term Response to PD-(L)1 Blockade in NSCLC

Matthew D. Hellmann, Barzin Y. Nabet, Hira Rizvi, Aadel A. Chaudhuri, Daniel K. Wells, Mark P.S. Dunphy, Jacob J. Chabon, Chih Long Liu, Angela B. Hui, Kathryn C. Arbour, Jia Luo, Isabel R. Preeshagul, Everett J. Moding, Diego Almanza, Rene F. Bonilla, Jennifer L. Sauter, Hyejin Choi, Megan Tenet, Mohsen Abu-Akeel, Andrew J. Plodkowski, Rocio Perez Johnston, Christopher H. Yoo, Ryan B. Ko, Henning Stehr, Linda Gojenola, Heather A. Wakelee, Sukhmani K. Padda, Joel W. Neal, Jamie E. Chaft, Mark G. Kris, Charles M. Rudin, Taha Merghoub, Bob T. Li, Ash A. Alizadeh, Maximilian Diehn
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (12): 2849–2858.
https://doi.org/10.1158/1078-0432.CCR-19-3418
Published: 15 June 2020
View article titled, Circulating Tumor DNA Analysis to Assess Risk of Progression after Long-term Response to PD-(L)1 Blockade in NSCLC
Open the PDF for Circulating Tumor DNA Analysis to Assess Risk of Progression after Long-term Response to PD-(L)1 Blockade in NSCLC in another window
Includes: Supplementary data
Journal Articles

Tumor Analyses Reveal Squamous Transformation and Off-Target Alterations As Early Resistance Mechanisms to First-line Osimertinib in EGFR-Mutant Lung Cancer

Adam J. Schoenfeld, Joseph M. Chan, Daisuke Kubota, Hiroki Sato, Hira Rizvi, Yahya Daneshbod, Jason C. Chang, Paul K. Paik, Michael Offin, Maria E. Arcila, Monika A. Davare, Ujwal Shinde, Dana Pe'er, Natasha Rekhtman, Mark G. Kris, Romel Somwar, Gregory J. Riely, Marc Ladanyi, Helena A. Yu
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (11): 2654–2663.
https://doi.org/10.1158/1078-0432.CCR-19-3563
Published: 01 June 2020
View article titled, Tumor Analyses Reveal Squamous Transformation and Off-Target Alterations As Early Resistance Mechanisms to First-line Osimertinib in <em>EGFR</em>-Mutant Lung Cancer
Open the PDF for Tumor Analyses Reveal Squamous Transformation and Off-Target Alterations As Early Resistance Mechanisms to First-line Osimertinib in <em>EGFR</em>-Mutant Lung Cancer in another window
Includes: Supplementary data
Journal Articles

A Phase II Trial of Albumin-Bound Paclitaxel and Gemcitabine in Patients with Newly Diagnosed Stage IV Squamous Cell Lung Cancers

Paul K. Paik, Rachel K. Kim, Linda Ahn, Andrew J. Plodkowski, Ai Ni, Mark T.A. Donoghue, Philip Jonsson, Miguel Villalona-Calero, Kenneth Ng, Daniel McFarland, John J. Fiore, Afsheen Iqbal, Juliana Eng, Mark G. Kris, Charles M. Rudin
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (8): 1796–1802.
https://doi.org/10.1158/1078-0432.CCR-19-3060
Published: 15 April 2020
View article titled, A Phase II Trial of Albumin-Bound Paclitaxel and Gemcitabine in Patients with Newly Diagnosed Stage IV Squamous Cell Lung Cancers
Open the PDF for A Phase II Trial of Albumin-Bound Paclitaxel and Gemcitabine in Patients with Newly Diagnosed Stage IV Squamous Cell Lung Cancers in another window
Includes: Supplementary data
Journal Articles

High Yield of RNA Sequencing for Targetable Kinase Fusions in Lung Adenocarcinomas with No Mitogenic Driver Alteration Detected by DNA Sequencing and Low Tumor Mutation Burden

Ryma Benayed, Michael Offin, Kerry Mullaney, Purvil Sukhadia, Kelly Rios, Patrice Desmeules, Ryan Ptashkin, Helen Won, Jason Chang, Darragh Halpenny, Alison M. Schram, Charles M. Rudin, David M. Hyman, Maria E. Arcila, Michael F. Berger, Ahmet Zehir, Mark G. Kris, Alexander Drilon, Marc Ladanyi
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (15): 4712–4722.
https://doi.org/10.1158/1078-0432.CCR-19-0225
Published: 01 August 2019
View article titled, High Yield of RNA Sequencing for Targetable Kinase Fusions in Lung Adenocarcinomas with No Mitogenic Driver Alteration Detected by DNA Sequencing and Low Tumor Mutation Burden
Open the PDF for High Yield of RNA Sequencing for Targetable Kinase Fusions in Lung Adenocarcinomas with No Mitogenic Driver Alteration Detected by DNA Sequencing and Low Tumor Mutation Burden in another window
Includes: Supplementary data
Journal Articles

Activation of KRAS Mediates Resistance to Targeted Therapy in MET Exon 14–mutant Non–small Cell Lung Cancer

Ken Suzawa, Michael Offin, Daniel Lu, Christopher Kurzatkowski, Morana Vojnic, Roger S. Smith, Joshua K. Sabari, Huichun Tai, Marissa Mattar, Inna Khodos, Elisa de Stanchina, Charles M. Rudin, Mark G. Kris, Maria E. Arcila, William W. Lockwood, Alexander Drilon, Marc Ladanyi, Romel Somwar
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (4): 1248–1260.
https://doi.org/10.1158/1078-0432.CCR-18-1640
Published: 15 February 2019
View article titled, Activation of KRAS Mediates Resistance to Targeted Therapy in MET Exon 14–mutant Non–small Cell Lung Cancer
Open the PDF for Activation of KRAS Mediates Resistance to Targeted Therapy in MET Exon 14–mutant Non–small Cell Lung Cancer in another window
Includes: Supplementary data
Journal Articles

Tumor Mutation Burden and Efficacy of EGFR-Tyrosine Kinase Inhibitors in Patients with EGFR-Mutant Lung Cancers

Michael Offin, Hira Rizvi, Megan Tenet, Andy Ni, Francisco Sanchez-Vega, Bob T. Li, Alexander Drilon, Mark G. Kris, Charles M. Rudin, Nikolaus Schultz, Maria E. Arcila, Marc Ladanyi, Gregory J. Riely, Helena Yu, Matthew D. Hellmann
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (3): 1063–1069.
https://doi.org/10.1158/1078-0432.CCR-18-1102
Published: 01 February 2019
View article titled, Tumor Mutation Burden and Efficacy of EGFR-Tyrosine Kinase Inhibitors in Patients with <em>EGFR</em>-Mutant Lung Cancers
Open the PDF for Tumor Mutation Burden and Efficacy of EGFR-Tyrosine Kinase Inhibitors in Patients with <em>EGFR</em>-Mutant Lung Cancers in another window
Includes: Supplementary data
Journal Articles

Concurrent Alterations in EGFR-Mutant Lung Cancers Associated with Resistance to EGFR Kinase Inhibitors and Characterization of MTOR as a Mediator of Resistance

Helena A. Yu, Ken Suzawa, Emmet Jordan, Ahmet Zehir, Ai Ni, Ryan Kim, Mark G. Kris, Matthew D. Hellmann, Bob T. Li, Romel Somwar, David B. Solit, Michael F. Berger, Maria Arcila, Gregory J. Riely, Marc Ladanyi
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (13): 3108–3118.
https://doi.org/10.1158/1078-0432.CCR-17-2961
Published: 01 July 2018
View article titled, Concurrent Alterations in EGFR-Mutant Lung Cancers Associated with Resistance to EGFR Kinase Inhibitors and Characterization of MTOR as a Mediator of Resistance
Open the PDF for Concurrent Alterations in EGFR-Mutant Lung Cancers Associated with Resistance to EGFR Kinase Inhibitors and Characterization of MTOR as a Mediator of Resistance in another window
Includes: Supplementary data
Journal Articles

The Impact of Smoking and TP53 Mutations in Lung Adenocarcinoma Patients with Targetable Mutations—The Lung Cancer Mutation Consortium (LCMC2)

Dara L. Aisner, Lynette M. Sholl, Lynne D. Berry, Michael R. Rossi, Heidi Chen, Junya Fujimoto, Andre L. Moreira, Suresh S. Ramalingam, Liza C. Villaruz, Gregory A. Otterson, Eric Haura, Katerina Politi, Bonnie Glisson, Jeremy Cetnar, Edward B. Garon, Joan Schiller, Saiama N. Waqar, Lecia V. Sequist, Julie Brahmer, Yu Shyr, Kelly Kugler, Ignacio I. Wistuba, Bruce E. Johnson, John D. Minna, Mark G. Kris, Paul A. Bunn, David J. Kwiatkowski
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (5): 1038–1047.
https://doi.org/10.1158/1078-0432.CCR-17-2289
Published: 28 February 2018
View article titled, The Impact of Smoking and TP53 Mutations in Lung Adenocarcinoma Patients with Targetable Mutations—The Lung Cancer Mutation Consortium (LCMC2)
Open the PDF for The Impact of Smoking and TP53 Mutations in Lung Adenocarcinoma Patients with Targetable Mutations—The Lung Cancer Mutation Consortium (LCMC2) in another window
Includes: Supplementary data
Journal Articles

Effects of Co-occurring Genomic Alterations on Outcomes in Patients with KRAS-Mutant Non–Small Cell Lung Cancer

Kathryn C. Arbour, Emmett Jordan, Hyunjae Ryan Kim, Jordan Dienstag, Helena A. Yu, Francisco Sanchez-Vega, Piro Lito, Michael Berger, David B. Solit, Matthew Hellmann, Mark G. Kris, Charles M. Rudin, Ai Ni, Maria Arcila, Marc Ladanyi, Gregory J. Riely
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (2): 334–340.
https://doi.org/10.1158/1078-0432.CCR-17-1841
Published: 15 January 2018
View article titled, Effects of Co-occurring Genomic Alterations on Outcomes in Patients with <em>KRAS</em>-Mutant Non–Small Cell Lung Cancer
Open the PDF for Effects of Co-occurring Genomic Alterations on Outcomes in Patients with <em>KRAS</em>-Mutant Non–Small Cell Lung Cancer in another window
Includes: Supplementary data
Journal Articles

A Novel Crizotinib-Resistant Solvent-Front Mutation Responsive to Cabozantinib Therapy in a Patient with ROS1-Rearranged Lung Cancer

Alexander Drilon, Romel Somwar, Jacob P. Wagner, Nadeem A. Vellore, Christopher A. Eide, Matthew S. Zabriskie, Maria E. Arcila, Jaclyn F. Hechtman, Lu Wang, Roger S. Smith, Mark G. Kris, Gregory J. Riely, Brian J. Druker, Thomas O'Hare, Marc Ladanyi, Monika A. Davare
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (10): 2351–2358.
https://doi.org/10.1158/1078-0432.CCR-15-2013
Published: 12 May 2016
View article titled, A Novel Crizotinib-Resistant Solvent-Front Mutation Responsive to Cabozantinib Therapy in a Patient with <em>ROS1</em>-Rearranged Lung Cancer
Open the PDF for A Novel Crizotinib-Resistant Solvent-Front Mutation Responsive to Cabozantinib Therapy in a Patient with <em>ROS1</em>-Rearranged Lung Cancer in another window
Includes: Supplementary data
Journal Articles

Broad, Hybrid Capture–Based Next-Generation Sequencing Identifies Actionable Genomic Alterations in Lung Adenocarcinomas Otherwise Negative for Such Alterations by Other Genomic Testing Approaches

Alexander Drilon, Lu Wang, Maria E. Arcila, Sohail Balasubramanian, Joel R. Greenbowe, Jeffrey S. Ross, Phil Stephens, Doron Lipson, Vincent A. Miller, Mark G. Kris, Marc Ladanyi, Naiyer A. Rizvi
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2015) 21 (16): 3631–3639.
https://doi.org/10.1158/1078-0432.CCR-14-2683
Published: 13 August 2015
View article titled, Broad, Hybrid Capture–Based Next-Generation Sequencing Identifies Actionable Genomic Alterations in Lung Adenocarcinomas Otherwise Negative for Such Alterations by Other Genomic Testing Approaches
Open the PDF for Broad, Hybrid Capture–Based Next-Generation Sequencing Identifies Actionable Genomic Alterations in Lung Adenocarcinomas Otherwise Negative for Such Alterations by Other Genomic Testing Approaches in another window
Includes: Supplementary data
Journal Articles

MAP2K1 (MEK1) Mutations Define a Distinct Subset of Lung Adenocarcinoma Associated with Smoking

Maria E. Arcila, Alexander Drilon, Brooke E. Sylvester, Christine M. Lovly, Laetitia Borsu, Boris Reva, Mark G. Kris, David B. Solit, Marc Ladanyi
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (8): 1935–1943.
https://doi.org/10.1158/1078-0432.CCR-14-2124
Published: 14 April 2015
View article titled, <em>MAP2K1</em> (<em>MEK1</em>) Mutations Define a Distinct Subset of Lung Adenocarcinoma Associated with Smoking
Open the PDF for <em>MAP2K1</em> (<em>MEK1</em>) Mutations Define a Distinct Subset of Lung Adenocarcinoma Associated with Smoking in another window
Includes: Supplementary data